PubMed:23941739 JSONTXT

{"project":"Allie","denotations":[{"id":"SS1_23941739_2_0","span":{"begin":287,"end":311},"obj":"expanded"},{"id":"SS2_23941739_2_0","span":{"begin":313,"end":316},"obj":"abbr"},{"id":"SS1_23941739_3_0","span":{"begin":319,"end":344},"obj":"expanded"},{"id":"SS2_23941739_3_0","span":{"begin":346,"end":349},"obj":"abbr"},{"id":"SS1_23941739_6_0","span":{"begin":584,"end":618},"obj":"expanded"},{"id":"SS2_23941739_6_0","span":{"begin":620,"end":624},"obj":"abbr"},{"id":"SS1_23941739_9_0","span":{"begin":1008,"end":1034},"obj":"expanded"},{"id":"SS2_23941739_9_0","span":{"begin":1036,"end":1040},"obj":"abbr"}],"relations":[{"id":"AE1_23941739_2_0","pred":"abbreviatedTo","subj":"SS1_23941739_2_0","obj":"SS2_23941739_2_0"},{"id":"AE1_23941739_3_0","pred":"abbreviatedTo","subj":"SS1_23941739_3_0","obj":"SS2_23941739_3_0"},{"id":"AE1_23941739_6_0","pred":"abbreviatedTo","subj":"SS1_23941739_6_0","obj":"SS2_23941739_6_0"},{"id":"AE1_23941739_9_0","pred":"abbreviatedTo","subj":"SS1_23941739_9_0","obj":"SS2_23941739_9_0"}],"text":"Three-month treatment with adaptive servoventilation improves cardiac function and physical activity in patients with chronic heart failure and cheyne-stokes respiration: a prospective randomized controlled trial.\nBACKGROUND: Cheyne-Stokes respiration frequently occurs in patients with congestive heart failure (CHF). Adaptive servoventilation (ASV) is a novel therapy with potential benefits. This prospective randomized trial investigated the effects of ASV on myocardial function and physical capacity.\nMETHODS: Patients with severe CHF, despite optimal cardiac medication and/or left ventricular ejection fraction (LVEF) ≤40% and Cheyne-Stokes breathing for \u003e25% of sleeping time were included. Fifty-one patients, age 57-81 years (4 were women), were randomized to either an ASV or a control group; 30 patients completed the study (15 from each group). The primary end point was any change in LVEF. The secondary end points were alterations in physical capacity according to the 6-min walk test or the New York Heart Association (NYHA) class.\nRESULTS: In the ASV-treatment group, LVEF improved from baseline (32 ± 11%) to study end (36 ± 13%), p = 0.013. The 6-min walk test improved from 377 ± 115 to 430 ± 123 m (p = 0.014) and the NYHA class from 3.2 (3.0-3.0) to 2.0 (2.0-3.0) (p \u003c 0.001). No changes occurred in the control group.\nCONCLUSION: Three months of ASV treatment improved LVEF and physical capacity in CHF patients with Cheyne-Stokes respiration. These results suggest that ASV may be a beneficial supplement to standard medication in these patients."}

{"project":"PubmedHPO","denotations":[{"id":"T1","span":{"begin":226,"end":251},"obj":"HP_0012196"},{"id":"T2","span":{"begin":287,"end":311},"obj":"HP_0001635"},{"id":"T3","span":{"begin":298,"end":311},"obj":"HP_0001635"}],"text":"Three-month treatment with adaptive servoventilation improves cardiac function and physical activity in patients with chronic heart failure and cheyne-stokes respiration: a prospective randomized controlled trial.\nBACKGROUND: Cheyne-Stokes respiration frequently occurs in patients with congestive heart failure (CHF). Adaptive servoventilation (ASV) is a novel therapy with potential benefits. This prospective randomized trial investigated the effects of ASV on myocardial function and physical capacity.\nMETHODS: Patients with severe CHF, despite optimal cardiac medication and/or left ventricular ejection fraction (LVEF) ≤40% and Cheyne-Stokes breathing for \u003e25% of sleeping time were included. Fifty-one patients, age 57-81 years (4 were women), were randomized to either an ASV or a control group; 30 patients completed the study (15 from each group). The primary end point was any change in LVEF. The secondary end points were alterations in physical capacity according to the 6-min walk test or the New York Heart Association (NYHA) class.\nRESULTS: In the ASV-treatment group, LVEF improved from baseline (32 ± 11%) to study end (36 ± 13%), p = 0.013. The 6-min walk test improved from 377 ± 115 to 430 ± 123 m (p = 0.014) and the NYHA class from 3.2 (3.0-3.0) to 2.0 (2.0-3.0) (p \u003c 0.001). No changes occurred in the control group.\nCONCLUSION: Three months of ASV treatment improved LVEF and physical capacity in CHF patients with Cheyne-Stokes respiration. These results suggest that ASV may be a beneficial supplement to standard medication in these patients."}

{"project":"Zierdiyeerkenaili_800_3","denotations":[{"id":"T1","span":{"begin":313,"end":316},"obj":"DP"},{"id":"T2","span":{"begin":537,"end":540},"obj":"DP"},{"id":"T3","span":{"begin":1423,"end":1426},"obj":"DP"},{"id":"T4","span":{"begin":287,"end":311},"obj":"DP"},{"id":"T7","span":{"begin":118,"end":139},"obj":"DP"}],"text":"Three-month treatment with adaptive servoventilation improves cardiac function and physical activity in patients with chronic heart failure and cheyne-stokes respiration: a prospective randomized controlled trial.\nBACKGROUND: Cheyne-Stokes respiration frequently occurs in patients with congestive heart failure (CHF). Adaptive servoventilation (ASV) is a novel therapy with potential benefits. This prospective randomized trial investigated the effects of ASV on myocardial function and physical capacity.\nMETHODS: Patients with severe CHF, despite optimal cardiac medication and/or left ventricular ejection fraction (LVEF) ≤40% and Cheyne-Stokes breathing for \u003e25% of sleeping time were included. Fifty-one patients, age 57-81 years (4 were women), were randomized to either an ASV or a control group; 30 patients completed the study (15 from each group). The primary end point was any change in LVEF. The secondary end points were alterations in physical capacity according to the 6-min walk test or the New York Heart Association (NYHA) class.\nRESULTS: In the ASV-treatment group, LVEF improved from baseline (32 ± 11%) to study end (36 ± 13%), p = 0.013. The 6-min walk test improved from 377 ± 115 to 430 ± 123 m (p = 0.014) and the NYHA class from 3.2 (3.0-3.0) to 2.0 (2.0-3.0) (p \u003c 0.001). No changes occurred in the control group.\nCONCLUSION: Three months of ASV treatment improved LVEF and physical capacity in CHF patients with Cheyne-Stokes respiration. These results suggest that ASV may be a beneficial supplement to standard medication in these patients."}

{"project":"yaoziqian_800_3","denotations":[{"id":"T3","span":{"begin":313,"end":316},"obj":"DP"},{"id":"T4","span":{"begin":537,"end":540},"obj":"DP"},{"id":"T5","span":{"begin":1423,"end":1426},"obj":"DP"},{"id":"T6","span":{"begin":118,"end":139},"obj":"DP"},{"id":"T7","span":{"begin":287,"end":311},"obj":"DP"}],"text":"Three-month treatment with adaptive servoventilation improves cardiac function and physical activity in patients with chronic heart failure and cheyne-stokes respiration: a prospective randomized controlled trial.\nBACKGROUND: Cheyne-Stokes respiration frequently occurs in patients with congestive heart failure (CHF). Adaptive servoventilation (ASV) is a novel therapy with potential benefits. This prospective randomized trial investigated the effects of ASV on myocardial function and physical capacity.\nMETHODS: Patients with severe CHF, despite optimal cardiac medication and/or left ventricular ejection fraction (LVEF) ≤40% and Cheyne-Stokes breathing for \u003e25% of sleeping time were included. Fifty-one patients, age 57-81 years (4 were women), were randomized to either an ASV or a control group; 30 patients completed the study (15 from each group). The primary end point was any change in LVEF. The secondary end points were alterations in physical capacity according to the 6-min walk test or the New York Heart Association (NYHA) class.\nRESULTS: In the ASV-treatment group, LVEF improved from baseline (32 ± 11%) to study end (36 ± 13%), p = 0.013. The 6-min walk test improved from 377 ± 115 to 430 ± 123 m (p = 0.014) and the NYHA class from 3.2 (3.0-3.0) to 2.0 (2.0-3.0) (p \u003c 0.001). No changes occurred in the control group.\nCONCLUSION: Three months of ASV treatment improved LVEF and physical capacity in CHF patients with Cheyne-Stokes respiration. These results suggest that ASV may be a beneficial supplement to standard medication in these patients."}